Last reviewed · How we verify
Lasix ONYU
Lasix (furosemide) is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.
Lasix (furosemide) is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
At a glance
| Generic name | Lasix ONYU |
|---|---|
| Sponsor | University of Florida |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This leads to increased urine output and reduced fluid volume in the body, lowering blood pressure and reducing edema. It is one of the most potent diuretics available and is commonly used in conditions requiring rapid fluid removal.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Edema associated with renal disease
- Hypertension
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
Key clinical trials
- Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (PHASE1)
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure (PHASE3)
- Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lasix ONYU CI brief — competitive landscape report
- Lasix ONYU updates RSS · CI watch RSS
- University of Florida portfolio CI